// App-Quantinova.ai

4501 : Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).

Researchers

Presenter

  • Dean F. Bajorin

Principal Investigators

  • David J. Vaughn

  • Yves Fradet

  • Jae-Lyun Lee

  • Lawrence Fong

  • Nicholas J. Vogelzang

  • Miguel Angel Climent

  • Daniel Peter Petrylak

  • Toni K. Choueiri

  • Andrea Necchi

  • Winald Gerritsen

  • Howard Gurney

  • David I Quinn

  • Stephane Culine

  • Cora N. Sternberg

  • Yabing Mai

  • Markus Puhlmann

  • Rodolfo F. Perini

  • Joaquim Bellmunt

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Abramson Cancer Center, Philadelphia, PA

  • CHU de Quebec - Universite Laval, Quebec City, QC, Canada

  • University of California, San Francisco, San Francisco, CA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Smilow Cancer Hospital, New Haven, CT

  • Dana-Farber Cancer Institute, Boston, MA

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Radboud University Medical Center, Njmegen, Netherlands

  • Westmead Hospital and Macquarie University, Sydney, Australia

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Hospital Saint Antoine, Paris, France

  • San Camillo-Forlanini Hospital, Rome, Italy

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • Canada

  • Italy

  • Netherlands

  • Spain

  • Australia

  • United States

  • France

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Paclitaxel

  • vinflunine

  • Docetaxel

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02256436

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved